News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
684,980 Results
Type
Article (39020)
Company Profile (279)
Press Release (645681)
Section
Business (203854)
Career Advice (1988)
Deals (35361)
Drug Delivery (85)
Drug Development (80784)
Employer Resources (168)
FDA (16086)
Job Trends (14802)
News (344516)
Policy (32433)
Tag
Academia (2530)
Alliances (49060)
Alzheimer's disease (1225)
Approvals (16013)
Artificial intelligence (125)
Bankruptcy (352)
Best Places to Work (11528)
Biotechnology (200)
Breast cancer (116)
Cancer (1031)
Cardiovascular disease (86)
Career advice (1658)
Cell therapy (220)
Clinical research (64122)
Collaboration (365)
Compensation (188)
COVID-19 (2528)
C-suite (87)
Data (1041)
Diabetes (150)
Diagnostics (6131)
Earnings (84795)
Employer resources (146)
Events (109340)
Executive appointments (279)
FDA (16591)
Funding (329)
Gene therapy (170)
GLP-1 (572)
Government (4322)
Healthcare (18663)
Infectious disease (2610)
Inflammatory bowel disease (104)
Interviews (308)
IPO (16284)
Job creations (3623)
Job search strategy (1416)
Layoffs (412)
Legal (7851)
Lung cancer (165)
Manufacturing (170)
Medical device (13169)
Medtech (13174)
Mergers & acquisitions (19135)
Metabolic disorders (390)
Neuroscience (1481)
NextGen Class of 2024 (6499)
Non-profit (4463)
Northern California (1413)
Obesity (226)
Opinion (178)
Patents (98)
People (56204)
Phase I (19906)
Phase II (28241)
Phase III (21063)
Pipeline (441)
Postmarket research (2553)
Preclinical (8471)
Radiopharmaceuticals (234)
Rare diseases (206)
Real estate (5889)
Regulatory (21493)
Research institute (2308)
Resumes & cover letters (349)
Southern California (1261)
Startups (3560)
United States (13007)
Vaccines (547)
Weight loss (165)
Date
Last 7 days (919)
Last 30 days (3407)
Last 365 days (35388)
2024 (32087)
2023 (40074)
2022 (51173)
2021 (55712)
2020 (54087)
2019 (46541)
2018 (35019)
2017 (32109)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (713)
Arizona (190)
Asia (37083)
Australia (6050)
California (3182)
Canada (1254)
China (237)
Colorado (142)
Connecticut (143)
Europe (79423)
Florida (438)
Georgia (112)
Illinois (336)
Indiana (190)
Kansas (96)
Maryland (567)
Massachusetts (2520)
Michigan (153)
Minnesota (268)
New Jersey (920)
New York (926)
North Carolina (689)
Northern California (1413)
Ohio (133)
Pennsylvania (815)
South America (1091)
Southern California (1261)
Texas (435)
Utah (88)
Washington State (351)
684,980 Results for "glycomine inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Glycomine Appoints Joshua Grass as Chairperson of Board of Directors
October 10, 2024
·
2 min read
Press Releases
Glycomine Receives FDA Fast Track Designation for GLM101 for the Treatment of PMM2-CDG
September 18, 2024
·
2 min read
Biotech Bay
Glycomine Announces Encouraging Efficacy Data from Ongoing Phase 2 Clinical Study in PMM2-CDG
Glycomine, Inc. announced the presentation of summary findings from its ongoing Phase 2 clinical study (GLM101-002) in adult patients with PMM2-CDG at the Rare Disease Day 2024 Symposium, CDG Scientific and Family Conference, that took place March 1-3 in San Diego.
March 4, 2024
·
3 min read
Business
Glycomine Appoints Dr. Rose Marino Chief Medical Officer
Glycomine, Inc., a clinical-stage biotechnology company focused on developing new therapies for serious orphan diseases, announced the appointment of Rose Marino, M.D. as Chief Medical Officer.
October 12, 2023
·
2 min read
Drug Development
Glycomine Announces First Pediatric Patient Dosed in Phase 2 Clinical Study of GLM101, a Potential Treatment for PMM2-CDG
Glycomine, Inc. announced the first pediatric patient has been dosed in a multi-center open-label Phase 2 study of GLM101.
December 11, 2023
·
2 min read
Biotech Bay
Data from Glycomine’s Ongoing Natural History Study Provides Insight into Clinical Measures and Biomarkers for PMM2-CDG
Glycomine, Inc., a biotechnology company focused on developing new therapies for orphan diseases, announced the presentation of summary findings from its ongoing natural history study at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium taking place August 29 to September 1 in Jerusalem.
August 30, 2023
·
3 min read
Biotech Bay
Glycomine Presents at ASHG 2023 Data from Ongoing Natural History Study with Insight into Genetic Mutations and Biomarkers for PMM2-CDG
Glycomine, Inc., a biotechnology company focused on developing new therapies for orphan diseases, announced the presentation of summary findings from its ongoing natural history study at the American Society for Human Genetics (ASHG) 2023 Annual Meeting taking place in Washington, DC.
November 2, 2023
·
3 min read
Drug Development
Glycomine Announces First Patient Dosed in Phase 2 Clinical Study of GLM101, a Potential Treatment for PMM2-CDG
Glycomine, Inc. today announced that the first patient has been dosed in a multi-center open-label Phase 2 study (ClinicalTrials.gov Identifier: NCT05549219) of GLM101, a targeted mannose-1-phosphate replacement therapy, in adult patients with phosphomannomutase 2-congenital disorder of glycosylation (PMM2-CDG).
January 9, 2023
·
2 min read
Press Releases
ABS Bio, Inc. announces strategic investment by 3 Boomerang Capital
◆Investment to support services growth. ◆Industry veterans join board of directors, including John Chickosky as Executive Chairman, and Greg Swanberg and Martin LeBlanc as Directors.
November 14, 2024
·
1 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
1 of 68,498
Next
